Marketing authorisation recommended to be withdrawn for preterm birth drug
A vote by an FDA committee has resulted in the suggestion that marketing authorisation is revoked for preterm birth treatment Makena.
List view / Grid view
News
Seasonal influenza vaccine market to be worth $6.5bn by 2028
The transition from egg-based towards cell-based, recombinant and universal influenza vaccines will drive growth in the seasonal influenza vaccine market, a report has said.
UK government invests in global partnership to treat gonorrhoea
The UK government will invest £3.5 million to help develop new antibitoic treatments for gonorrhoea and make them available to low- and middle-income countries.
Ten European countries enter initiative to lower drug prices
A scheme called the International Horizon Scanning Initiative will allow ten European countries to work together on a database of medicines and reduce drug prices.
Relapsing multiple sclerosis drug approved by FDA
VUMERITY has been granted approved by the FDA for the treatment of relapsing forms of multiple sclerosis based on data from a New Drug Application submission.
FDA proposes three solutions to mitigate drug shortages
The FDA has compiled a report which identifies the root causes of medicine shortages and suggests potential ways to alleviate scarcities.
Candidate vaccine shows sustained protection against pulmonary TB
A candidate TB vaccine’s efficacy level and acceptable safety profile have been confirmed in a three-year clinical trial.
Drones faster than ambulances at delivering drugs
A study has revealed that drones can deliver medications to patients faster than ambulances during rush hour in New York.
CAR-T cell therapy granted RMAT for relapsed/refractory multiple myeloma
An investigational CT053 CAR-T cell therapy for RRMM has been given Regenerative Medicine Advanced Therapy designation.
Allergan to reportedly settle Alzheimer’s therapy lawsuit for $750m
Allergen is to reportedly settle a class-action lawsuit which alleges that it worked to delay generic competition for Alzheimer’s disease therapy Namenda.
Mylan announces voluntary recall of Alprazolam tablets
Due to possible contamination from a foreign substance, Mylan Pharmaceuticals is voluntarily recalling one batch of its Alprazolam tablets.
Life sciences sector at biggest risk of internal information leaks
Researchers have found that 33 percent of companies in the life sciences sector experienced an information leak within the last year.
Researchers suggest distorted spheres as form of drug delivery
A study has shown that macroscopic hollow spheres can be distorted to deflate and potentially release their contents, which could be imitated by microscopic drug delivery techniques.
AML gilteritinib treatment approved by the European Commission
XospataTM (gilteritinib) has been approved as a monotherapy for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation.
‘Revolutionary’ liquid sickle cell treatment has been unveiled
A new liquid formulation of hydroxycarbamide to treat sickle cell disease will “enable doctors to personalise doses in children".
